1
|
Watts MJ, Argyraki A, Barbieri M, Brown A, Button M, Finkelman R, Gibson G, Humphrey O, Huo X, Hursthouse AS, Kaninga B, Marinho Reis P, Middleton DRS, Morton-Bermea O, Nazarpour A, Olatunji AS, Osano O, Potgieter-Vermaak S, Prater C, Torrance K, Wong MH, Zhang C, Zia M. Editorial: The society for environmental geochemistry and health (SEGH): 50 years and beyond. Environ Geochem Health 2023; 45:1165-1171. [PMID: 35044549 PMCID: PMC8768439 DOI: 10.1007/s10653-021-01192-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/14/2021] [Accepted: 12/23/2021] [Indexed: 06/14/2023]
Abstract
When the SEGH international board released a short editorial paper back in 2019, we described an aim to increase the membership offering, whilst improving the diversity of input regionally, by scientific discipline and to ensure greater and more regular contact across the regions from 2020 onwards. Wider aspirations described in 2019 (Watts et al. 2019) are discussed within this short communication at the end of 2021 to evaluate progress made. In particular, how the SEGH community adapted to the unprecedented circumstances that have challenged each and every one of us throughout the COVID-19 pandemic since early 2020 and are likely to influence our activities for the foreseeable future.
Collapse
Affiliation(s)
- M. J. Watts
- Inorganic Geochemistry, British Geological Survey, Nottingham, UK
| | - A. Argyraki
- Department of Geology and Geoenvironment, National and Kapodistrian University of Athens, Athens, Greece
| | | | - A. Brown
- SEGH, British Geological Survey, Nottingham, UK
| | - M. Button
- University British Columbia, Kalowna, Canada
| | | | - G. Gibson
- Gibson Consulting and Training, Tarporley, UK
| | - O. Humphrey
- Inorganic Geochemistry, British Geological Survey, Nottingham, UK
| | - X. Huo
- School of Environment, Jinan University, Guangzhou, China
| | | | - B. Kaninga
- Zambia Agriculture Research Institute, Mount Makulu Central Research Station, P/B 7, Chilanga, Zambia
| | - P. Marinho Reis
- Departamento de Ciências da Terra, Escola de Ciências, Universidade do Minho, Campus de Gualtarl, Braga, Portugal
| | - D. R. S. Middleton
- Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast, UK
| | - O. Morton-Bermea
- Instituto ed Geofísica, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - A. Nazarpour
- Department of Geology, Islamic Azad University, Ahvaz Branch, Ahvaz, Iran
| | - A. S. Olatunji
- Department of Geology, University of Ibadan, Ibadan, Nigeria
| | - O. Osano
- Department of Environmental Biology and Health, School of Environmental Studies, University of Eldoret, Eldoret, Kenya
| | | | - C. Prater
- Oklahoma State University, Stillwater, USA
| | | | - M. H. Wong
- The Education University of Hong Kong, Hong Kong, China
| | - C. Zhang
- National University of Ireland, Galway, Ireland
| | - M. Zia
- Fauji Fertiliser Company Ltd, Rawalpindi, Pakistan
| |
Collapse
|
2
|
Gomez N, Porther R, John R, Evans P, Shaw P, Button M, Williams S, Williamson I, Ionescu A. Mesothelioma: diagnosis, treatment and survival in a large teaching hospital. Lung Cancer 2020. [DOI: 10.1016/s0169-5002(20)30192-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
3
|
Deist T, Dankers F, Ojha P, Marshall S, Janssen T, Faivre-Finn C, Masciocchi C, Valentini V, Wang J, Chen J, Zhang Z, Spezi E, Button M, Nuyttens J, Vernhout R, Van Soest J, Jochems A, Monshouwer R, Bussink J, Price G, Lambin P, Dekker A. OC-0544 Distributed learning on 20 000+ lung cancer patients. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)30964-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
4
|
Sanganalmath P, Lester JE, Bradshaw AG, Das T, Esler C, Roy AEF, Toy E, Lester JF, Button M, Wilson P, Comins C, Atherton P, Pickles R, Foweraker K, Walker GA, Keni M, Hatton MQ. Continuous Hyperfractionated Accelerated Radiotherapy (CHART) for Non-small Cell Lung Cancer (NSCLC): 7 Years' Experience From Nine UK Centres. Clin Oncol (R Coll Radiol) 2018; 30:144-150. [PMID: 29336865 DOI: 10.1016/j.clon.2017.12.019] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2017] [Revised: 08/27/2017] [Accepted: 11/06/2017] [Indexed: 01/15/2023]
Abstract
AIM Continuous hyperfractionated accelerated radiotherapy (CHART) remains an option to treat non-small cell lung cancer (NSCLC; NICE, 2011). We have previously published treatment outcomes from 1998-2003 across five UK centres. Here we update the UK CHART experience, reporting outcomes and toxicities for patients treated between 2003 and 2009. MATERIALS AND METHODS UK CHART centres were invited to participate in a retrospective data analysis of NSCLC patients treated with CHART from 2003 to 2009. Nine (of 14) centres were able to submit their data into a standard database. The Kaplan-Meier method estimated survival and the Log-rank test analysed the significance. RESULTS In total, 849 patients had CHART treatment, with a median age of 71 years (range 31-91), 534 (63%) were men, 55% had undergone positron emission tomography-computed tomography (PET-CT) and 26% had prior chemotherapy; 839 (99%) patients received all the prescribed treatment. The median overall survival was 22 months with 2 and 3 year survival of 47% and 32%, respectively. Statistically significant differences in survival were noted for stage IA versus IB (33.2 months versus 25 months; P = 0.032) and IIIA versus IIIB (20 months versus 16 months; P = 0.018). Response at 3 months and outcomes were significantly linked; complete response showing survival of 34 months against 19 months, 15 months and 8 months for partial response, stable and progressive disease, respectively (P < 0.001). Age, gender, performance status, prior chemotherapy and PET-CT did not affect the survival outcomes. Treatment was well tolerated with <5% reporting ≥grade 3 toxicity. CONCLUSION In routine practice, CHART results for NSCLC remain encouraging and we have been able to show an improvement in survival compared with the original trial cohort. We have confirmed that CHART remains deliverable with low toxicity rates and we are taking a dose-escalated CHART regimen forward in a randomised phase II study of sequential chemoradiotherapy against other accelerated dose-escalated schedules.
Collapse
Affiliation(s)
| | | | - A G Bradshaw
- Weston Park Hospital, Sheffield, UK; Newcastle on Tyne Hospitals NHS Trust, Freeman Hospital, Newcastle, UK
| | - T Das
- Weston Park Hospital, Sheffield, UK
| | - C Esler
- University Hospitals of Leicester NHS Trust, Leicester, UK
| | - A E F Roy
- Plymouth Hospitals NHS Trust, Plymouth, UK
| | - E Toy
- Royal Devon and Exeter NHS Foundation Trust, Exeter, UK
| | | | - M Button
- Velindre Cancer Centre, Cardiff, UK
| | - P Wilson
- University Hospitals Bristol NHS Trust, Bristol, UK
| | - C Comins
- University Hospitals Bristol NHS Trust, Bristol, UK
| | - P Atherton
- Newcastle on Tyne Hospitals NHS Trust, Freeman Hospital, Newcastle, UK
| | - R Pickles
- Newcastle on Tyne Hospitals NHS Trust, Freeman Hospital, Newcastle, UK
| | - K Foweraker
- Nottingham University Hospitals NHS Trust, City Hospital, Nottingham, UK
| | - G A Walker
- Derby Hospitals NHS Trust, Royal Derby Hospital, UK
| | - M Keni
- Derby Hospitals NHS Trust, Royal Derby Hospital, UK
| | | |
Collapse
|
5
|
Tanguay JS, Catlow C, Smith C, Barber J, Staffurth J, Kumar S, Palaniappan N, Button M, Mason MD. High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice. Clin Oncol (R Coll Radiol) 2016; 28:611. [PMID: 27131755 DOI: 10.1016/j.clon.2016.03.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2016] [Revised: 03/11/2016] [Accepted: 03/31/2016] [Indexed: 10/21/2022]
Affiliation(s)
| | | | - C Smith
- Velindre Cancer Centre, Cardiff, UK
| | - J Barber
- Velindre Cancer Centre, Cardiff, UK
| | | | - S Kumar
- Velindre Cancer Centre, Cardiff, UK
| | | | - M Button
- Velindre Cancer Centre, Cardiff, UK
| | | |
Collapse
|
6
|
Button M, Evans R, Rees E, Bullock C. Review of Radical Radiotherapy +/- Chemotherapy for Stage III Nsclc. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv049.05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
7
|
Button M, Evans R, Bullock C, Rees E. Social Deprivation and Radical Treatment of Stage III Nsclc. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv049.12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
8
|
Evans R, Johns E, Button M, Brewster A, Hanna L, Lester J, Tanguay J. 68: Surgical resection and adjuvant chemotherapy in non small cell lung cancer (NSCLC): a review of practice in South East Wales. Lung Cancer 2015. [DOI: 10.1016/s0169-5002(15)50067-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
9
|
Khan F, Ottensmeier C, Popat S, Dua D, Dorey N, Ellis S, Szabo M, Upadhyay S, Califano R, Chan S, Lee L, Ali CW, Nicolson M, Bates AT, Button M, Chaudhuri A, Mulvenna P, Shaw HM, Danson SJ. Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient Programme. Eur J Cancer 2014; 50:1717-1721. [PMID: 24726055 DOI: 10.1016/j.ejca.2014.03.001] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2014] [Revised: 02/26/2014] [Accepted: 03/02/2014] [Indexed: 01/08/2023]
Abstract
INTRODUCTION Afatinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) who were previously sensitive to erlotinib or gefitinib. This study investigated experience of afatinib under a Named Patient Use (NPU) programme. PATIENTS AND METHODS Retrospective data for 63 patients were collected, including demographics, dose, toxicity and clinical efficacy. RESULTS Response rate and median PFS were 14.3% and 2.6months, respectively. Diarrhoea and rash were the most common toxicities; 46% of patients required a dose reduction and 41% had a dose delay. CONCLUSIONS Efficacy and safety in the NPU programme are consistent with the LUX-Lung 1 trial.
Collapse
Affiliation(s)
- F Khan
- Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield S10 2SJ, United Kingdom
| | - C Ottensmeier
- Southampton NIHR Experimental Cancer Medicine Center and Southampton University Hospitals NHS Foundation, Southampton SO16 6YD, United Kingdom
| | - S Popat
- Royal Marsden Hospital, London SW3 6JJ, United Kingdom
| | - D Dua
- Guy's and St. Thomas' NHS Foundation Trust, London SE1 9RT, United Kingdom
| | - N Dorey
- Royal Devon and Exeter NHS Foundation Trust, Exeter EX2 5DW, United Kingdom
| | - S Ellis
- Royal Bournemouth Hospital, Bournemouth BH7 7DW, United Kingdom
| | - M Szabo
- Southampton NIHR Experimental Cancer Medicine Center and Southampton University Hospitals NHS Foundation, Southampton SO16 6YD, United Kingdom
| | - S Upadhyay
- Hull and East Yorkshire Hospitals NHS Trust, Hull HU16 5JQ, United Kingdom
| | - R Califano
- Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, United Kingdom
| | - S Chan
- Harrogate and District NHS Foundation Trust, Harrogate HG2 7SX, United Kingdom
| | - L Lee
- Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, United Kingdom
| | - C W Ali
- Beatson West of Scotland Cancer Centre, Glasgow G12 0YN, United Kingdom
| | - M Nicolson
- Aberdeen Royal Infirmary, Aberdeen AB25 2ZN, United Kingdom
| | - A T Bates
- Southampton NIHR Experimental Cancer Medicine Center and Southampton University Hospitals NHS Foundation, Southampton SO16 6YD, United Kingdom
| | - M Button
- Velindre Cancer Centre, Cardiff CF14 2TL, United Kingdom
| | - A Chaudhuri
- United Lincolnshire Hospitals NHS Trust, Lincoln LN2 5QY, United Kingdom
| | - P Mulvenna
- Newcastle upon Tyne NHS Foundation Trust, Newcastle NE7 7DN, United Kingdom
| | - H M Shaw
- University College London Hospitals NHS Foundation Trust, London NW1 2PG, United Kingdom
| | - S J Danson
- Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield S10 2SJ, United Kingdom.
| |
Collapse
|
10
|
Rackley T, Vines L, Palaniappan N, Staffurth J, Button M, Tanguay J. Concurrent Chemoradiotherapy for Muscle-invasive Bladder Cancer Using Weekly Cisplatin or Capecitabine and Mitomycin C — A Review of Practice Post BC2001. Clin Oncol (R Coll Radiol) 2014. [DOI: 10.1016/j.clon.2013.11.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
11
|
Tanguay J, Wheeler P, Button M, Stevens R, Shaw P, Brewster A, Hanna L, Lester J. 179 Limited stage small cell lung cancer (LS SCLC) – South East Wales experience. Lung Cancer 2014. [DOI: 10.1016/s0169-5002(14)70180-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
12
|
Hett K, Tanguay J, Button M. 182 Survival in stage IV small cell lung cancer and effect of prophylactic cranial irradiation. Lung Cancer 2014. [DOI: 10.1016/s0169-5002(14)70183-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
13
|
Sweeney L, Sneller S, Button M, Barber J, Lester J, Staffurth J. The Use of Strontium-89 in Castration-resistant Metastatic Prostate Cancer at Velindre Hospital. Clin Oncol (R Coll Radiol) 2013. [DOI: 10.1016/j.clon.2012.12.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
14
|
Caley A, Argyle G, Barber J, Button M, Lester J, Staffurth J. The Outcomes of Patients Treated with Abiraterone Acetate Outside of Clinical Trials at Velindre Hospital. Clin Oncol (R Coll Radiol) 2013. [DOI: 10.1016/j.clon.2012.12.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
15
|
Watts MJ, Barlow TS, Button M, Sarkar SK, Bhattacharya BD, Alam MA, Gomes A. Arsenic speciation in polychaetes (Annelida) and sediments from the intertidal mudflat of Sundarban mangrove wetland, India. Environ Geochem Health 2013; 35:13-25. [PMID: 22736103 DOI: 10.1007/s10653-012-9471-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/03/2011] [Accepted: 06/06/2012] [Indexed: 06/01/2023]
Abstract
This paper documents the concentration of total arsenic and individual arsenic species in four soft-bottom benthic polychaetes (Perenereis cultifera, Ganganereis sootai, Lumbrinereis notocirrata and Dendronereis arborifera) along with host sediments from Sundarban mangrove wetland, India. An additional six sites were considered exclusively for surface sediments for this purpose. Polychaetes were collected along with the host sediments and measured for their total arsenic content using inductively coupled plasma mass spectrometry. Arsenic concentrations in polychaete body tissues varied greatly, suggesting species-specific characteristics and inherent peculiarities in arsenic metabolism. Arsenic was generally present in polychaetes as arsenate (As(V) ranges from 0.16 to 0.50 mg kg(-1)) or arsenite (As(III) ranges from 0.10 to 0.41 mg kg(-1)) (30-53 % as inorganic As) and dimethylarsinic acid (DMA(V) <1-25 %). Arsenobetaine (AB < 16 %), and PO(4)-arsenoriboside (8-48 %) were also detected as minor constituents, whilst monomethylarsonic acid (MA(V)) was not detected in any of the polychaetes. The highest total As (14.7 mg kg(-1) dry wt) was observed in the polychaete D. arborifera collected from the vicinity of a sewage outfall in which the majority of As was present as an uncharacterised compound (10.3 mg kg(-1) dry wt) eluted prior to AB. Host sediments ranged from 2.5 to 10.4 mg kg(-1) of total As. This work supports the importance of speciation analysis of As, because of the ubiquitous occurrence of this metalloid in the environment, and its variable toxicity depending on chemical form. It is also the first work to report the composition of As species in polychaetes from the Indian Sundarban wetlands.
Collapse
Affiliation(s)
- M J Watts
- British Geological Survey, Nottingham, UK.
| | | | | | | | | | | | | |
Collapse
|
16
|
Button M, Caley A, Cox R, White C. 140 FDG positron emission tomography maximum standardised uptake value (SUVmax) has prognostic value in non-small cell lung cancer treated with radical radiotherapy. Lung Cancer 2012. [DOI: 10.1016/s0169-5002(12)70141-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
17
|
|
18
|
Currie S, Butler R, Tanguay J, Button M, Brewster A, Stevens R, Lester J. 37 Experiences in epidermal growth factor receptor tyrosine kinase mutation testing in South East Wales. Lung Cancer 2011. [DOI: 10.1016/s0169-5002(11)70037-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
19
|
Brewster A, Jordan C, Gunter T, Poole S, Button M, Hanna L, Stevens R, Lester J. 14 Results of patient satisfaction survey conducted across SE Wales on patients undergoing chemotherapy for lung cancer. Lung Cancer 2011. [DOI: 10.1016/s0169-5002(11)70014-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
20
|
Wills L, Hudson E, Button M, Fenwick J, Macbeth F, Lester J. 40 Isotoxic hypofractionated radical radiotherapy for non-small cell lung cancer. Lung Cancer 2007. [DOI: 10.1016/s0169-5002(07)70366-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
21
|
Button M, Staffurth J, Crosby T. National Variations in the Treatment of Oesophageal Carcinoma with Chemo-radiotherapy. Clin Oncol (R Coll Radiol) 2007. [DOI: 10.1016/j.clon.2007.01.342] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
22
|
|
23
|
Abstract
The use of a pedicled, osteocutaneous groin flap to reconstruct a composite, interpositional loss of tissue in the thumb is reported. The bone is transferred as a living segment, not a dying graft, and hence affords the rapidity and strength of primary bony union.
Collapse
|
24
|
Abstract
Epitheloid sarcoma of the pulp of the thumb followed repeated penetrating injuries to the digit. It was treated aggressively and successfully to date, nearly 5 years later. In some respects this case report parallels those animal experiments in which foreign body tumorigenesis has been demonstrated, and one might entertain a correlation.
Collapse
|
25
|
Button M. Proceedings: Ultrastructure of sheep sweat glands in dilated and contracted states. J Anat 1973; 116:479. [PMID: 4791430] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
|
26
|
Button M. Scientific Freedom and Social Medicine. West J Med 1943. [DOI: 10.1136/bmj.1.4291.427-b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
27
|
|
28
|
Button M. THE PATH OF TOXINS TO THE CENTRAL NERVOUS SYSTEM. West J Med 1921; 1:853-4. [DOI: 10.1136/bmj.1.3154.853] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|